AC3056

AC3056 Uses, Dosage, Side Effects, Food Interaction and all others data.

AC3056 is a non-peptide antioxidant that acts as an inhibitor of vascular cell adhesion molecule expression originally developed by Aventis Pharmaceuticals. It as since been acquired by Amylin Pharmaceuticals and has completed phase I trials.

Oral administration of AC3056 results in dose-dependent antioxidant activity and was well tolerated. In 2002, positive results were reported from a phase I trial. In the double-blind, placebo-controlled, crossover trial, 14 healthy subjects received an oral formulation of AC3056 in a dose-escalating manner. Results demonstrated dose-dependent increases in blood levels of AC3056, as well as dose-dependent increases in serum antioxidant activity. The drug was well tolerated with no safety concerns.

Table Of contents

• AC3056
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	AC3056
Generic	AC3056
Type
Groups	Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

For the treatment of atherosclerosis and other conditions related to the obstruction of blood vessels.

Elimination Route

Absorbed following oral administration.

Innovators Monograph

You find simplified version here AC3056